Inovio Pharmaceuticals, Inc. - Common Stock (INO)

Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Inovio Pharmaceuticals, Inc. (“Inovio” or the “Company”) (NASDAQ: INO) investors concerning the Company’s possible violations of the federal securities laws.

Law Offices of Howard G. Smith announces an investigation on behalf of Inovio Pharmaceuticals, Inc. (“Inovio” or the “Company”) (NASDAQ: INO) investors concerning the Company’s possible violations of federal securities laws.

The Law Offices of Frank R. Cruz announces an investigation of Inovio Pharmaceuticals, Inc. (“Inovio” or the “Company”) (NASDAQ: INO) on behalf of investors concerning the Company’s possible violations of federal securities laws.

The DJS Law Group reminds investors of a class action lawsuit against Inovio Pharmaceuticals, Inc. (“Inovio” or “the Company”) (NASDAQ: INO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Inovio (INO) To Contact Him Directly To Discuss Their Options

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Inovio Pharmaceuticals, Inc. (“Inovio” or “the Company”) (NASDAQ: INO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) between October 10, 2023 and December 26, 2025. Inovio describes itself as a “biotechnology company focused on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with, inter alia, human papillomavirus (“HPV”).”

Robbins LLP informs stockholders that a class action was filed on behalf of all persons that purchased or otherwise acquired Inovio Pharmaceuticals, Inc. (NASDAQ: INO) securities between October 10, 2023 and December 26, 2025. Inovio is a biotechnology company focused on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with, inter alia, human papillomavirus (“HPV”).

NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Inovio Pharmaceuticals, Inc. (“Inovio” or the “Company”) (NASDAQ: INO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Inovio Pharmaceuticals, Inc. (“Inovio” or the “Company”) (NASDAQ: INO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Inovio Pharmaceuticals, Inc. (“Inovio” or the “Company”) (NASDAQ: INO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Inovio Pharmaceuticals, Inc. (“Inovio” or the “Company”) (NASDAQ: INO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Inovio Pharmaceuticals, Inc. (“Inovio” or the “Company”) (NASDAQ: INO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

LONDON and PHILADELPHIA, July 01, 2025 (GLOBE NEWSWIRE) -- Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, today announces the appointment of David Liebowitz, M.D., Ph.D. as Chief Medical Officer (CMO) and Yulii Bogatyrenko as an advisor in business development. Dr. Liebowitz will lead the Company’s clinical strategy and execution as it continues to advance its pipeline of targeted cancer therapies and Mr. Bogatyrenko will add additional strength to the Group’s business development strategy.

EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:MRNA),(NYSE:PFE),(NASDAQ:VIR),(NASDAQ:INO) EQNX::TICKER_END

PALM BEACH, Fla., Sept. 04, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The emergence of SARS-CoV-2, which triggered the COVID-19 pandemic with overall is widely regarded as the greatest medical emergency of the twentieth century. COVID-19’s impact on global society would be felt for a long time. Nonetheless, significant investment in life sciences in the last few decades has facilitated a rapid scientific response through advances in viral characterization, testing, and sequencing. A report from Transparency Market Research projects that the global COVID-19 therapeutics market size is projected to reach more than US$ 16.2 Bn by the end of 2031. The report continued: “The coronavirus treatment, and vaccination market witnessed significant increase in demand due to the desire of governments and people to safeguard themselves and their loved ones from the virus. Technology advancements have facilitated the rapid development of COVID medications therapies and vaccinations. In a relatively short amount of time, emerging technologies, such as CRISPR and mRNA, have made it possible to develop new medicines. Pharmaceutical corporations, biotech companies, academic institutions, and governmental entities have worked closely together to create COVID-19 treatments. New therapies and vaccines have been developed and distributed more rapidly because of this collaboration.” Active companies in the biotech industry this week include Sunshine Biopharma Inc. (NASDAQ: SBFM), Moderna, Inc. (NASDAQ: MRNA), Pfizer Inc. (NYSE: PFE), Vir Biotechnology, Inc. (NASDAQ: VIR), INOVIO (NASDAQ: INO).

Novavax navigates legal settlements, earnings expectations, and competition, hoping their protein-based vaccines become a global health game-changer.

Plymouth Meeting, Pa., June 23, 2023 (GLOBE NEWSWIRE) --

EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:MRNA),(NASDAQ:NVAX),(NASDAQ:VIR),(NASDAQ:INO) EQNX::TICKER_END

EQNX::TICKER_START (OTCQB:BIXT),(NASDAQ:NVAX),(NYSE:PFE),(NASDAQ:MRNA),(NASDAQ:INO),(NASDAQ:BNTX) EQNX::TICKER_END

Investing in biotech stocks carries both risk and reward. This article highlights two biotech companies that may appeal to specific investing styles

Amarin recently announced its earnings for Q2'22 with mixed results. Here we'll examine the pros and cons of having this penny stock in your portfolio.

FN Media Group Presents USA News Group News Commentary   Vancouver, BC –November 9, 2021 – USA News Group  –  After the launch of US President Joe Biden’s pushing of mandatory vaccination/testing in the workplace, new problems have arisen, such as expensive testing costs, and rampant supply shortages. On top of that, accuracy issues have […]

Palm Beach, FL – January 20, 2022 – FinancialNewsMedia.com News Commentary – Cloud computing increases real-time data collection and improves accessibility to the data. It has outpaced the conventional paper healthcare system by providing more speed and efficiency in data handling. For instance, cloud computing technology is widely used in remote patient monitoring. Rising demand […]

Palm Beach, FL – October 20, 2021 – FinancialNewsMedia.com News Commentary – Recently, scientific reports have shown that a universal coronavirus vaccine that protects against COVID-19 causing SARS-CoV-2, as well as other coronaviruses such as those causing SARS and MERS, produced promising results in a mouse study. Multiple SARS-CoV-2 vaccines have gone from development to […]